MIRA: רווח למניה בשנים עשר החודשים האחרונים MIRA Pharmaceuticals Inc.

MIRA Pharmaceuticals delegates drug development and testing to external contractors, as evidenced by the net income per share over 12 months, where the latest figure stands at -1.38. This model relies on CDMO facilities in Florida for molecule synthesis. However, stringent FDA and DEA oversight limits the commercial potential of their cannabinoid system, creating value trap risks when analyzing the asset.
פילוחים אנליטיים של חברת MIRA Pharma (MIRA)

MIRA Pharmaceuticals is scaling the development of plant-based non-opioid analgesics while minimizing specific scientific risks. This metric aggregates net income over four quarters divided by the total number of outstanding shares. The investor assesses the real efficiency of capitalization, separating operational resilience from market volatility. The trend of this value determines the pace of innovation monetization. Analyzing the annual earnings per share (EPS) allows for the identification of stagnation or growth in the business's fundamental value.